Control of lipids at baseline in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial

Preventive Cardiology

Volumn 12, Issue 1, 2009, Pages 9-18

  Pambianco, Georgia ^a   Lombardero, Manuel ^a   Bittner, Vera ^b   Forker, Alan ^c   Kennedy, Frank ^d   Krishnaswami, Ashok ^e   Mooradian, Arshag D ^f   Pop Busui, Rodica ^g   Rana, Jamal S ^a   Rodriguez, Annabelle ^h   Steffes, Michael ⁱ   Orchard, Trevor J ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b University of Alabama at Birmingham   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e KAISER PERMANENTE MEDICAL CENTER   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h JOHNS HOPKINS HOSPITAL   (United States)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; BILE ACID; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; RESIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DYSLIPIDEMIA; EDUCATION; FEMALE; GENDER; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; FOLLOW UP; METHODOLOGY; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 63849162080     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2008.00014.x     Document Type: Article

References (32)

1. Wild S, Roglic G, Green A. Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27(5):1047-1053.
2. Wingard DL, Barrett-Connor E. Heart disease and diabetes. Diabetes in America 1995, 429-440. 2nd ed, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases, NIH Publication No. 95-1468
3. Haffner SM, Lehto S, Ronnemaa T. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Eng J Med. 1998, 339(4):229-234.
4. Lee WL, Cheung AM, Cape D. Impact of diabetes and coronary artery disease in women and men. Diabetes Care. 2000, 23(7):962-968.
5. Betteridge DJ. Diabetic dyslipidaemia: treatment implications. J Intern Med. 1994, 236(suppl 736):47-52.
6. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003, 26(suppl 1):583-586.
7. Shepherd J, Barter P, Carmena R. Waters D for the treating to new targets investigators: effect of lowering LDL cholesterol substantially below currently recommended values in patients with coronary heart disease and diabetes: the Treating to Targets (TNT) Study. Diabetes Care. 2006, 29(6):1220-1226.
8. Colhoun HM, Betteridge DJ, Durrington PN. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Multicenter randomized placebo-controlled trial. Lancet. 2004, 364:685-696.
9. Knopp RH, d'Emden M, Smilde JG. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes. Diabetes Care. 2006, 29(7):1478-1485.
10. Grundy SM, Cleeman JI, Bairey NB. Stone NJ for the Coordinating Committee of the National Cholesterol Education Program: implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004, 110:227-239.
11. Putzer G, Roetzbeim R, Ramirez AM. Compliance with recommendations for lipid management among patients with type 2 diabetes in an academic family practice. J Am Board Fam Pract. 2004, 17:101-107.
12. Brooks MM, Frye RL, Genuth S. Hypotheses, design, and methods for the Bpass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol. 2006, 97(suppl):9G-19G.
13. Allain CC, Poon LS, Chan CSG. Enzymatic determination of total serum cholesterol. Clin Chem. 1974, 20:470-475.
14. Bucolo G, David H. Quantitative determination of serum triglyceride by the use of enzymes. Clin Chem. 1973, 19:476-482.
15. Warnick GR, Abers JJ. Heparin-Mn2+ quantitation of high-density lipoprotein cholesterol; an ultrafiltration procedure for lipemic samples. Clin Chem. 1978, 24:900-904.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18(6):499-502.
17. Official norm of the Ministry of Health of Mexico for prevention and treatment of hypercholesterolemia. 2003, July
18. Fodor JG, Frohlich JJ, Genest JJG. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ. 2000, 162(10):1441-1447.
19. Detecção, avaliação e tratamento. Arq Bras Cardiol. 1996, 67:1-16.
20. De Backer G, Ambrosioni E, Borch-Johnsen K. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis. 2004, 173:381-391.
21. Summary of Revisions for the 2007 Clinical Practice Recommendations. Diabetes Care. 2007, 30(suppl I):S3.
22. Wexler DJ, Grant RW, Meigs JB. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care. 2005, 28(3):514-520.
23. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999, 281(14):1291-1297.
24. Gowri MS, Van der Westhuyzen DR, Bridges SR. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Artherioscler Thromb Vasc Biol. 2006, 19:2226-2233.
25. Safford M, Eaton L, Hawley G. Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus. Arch Intern Med. 2003, 163:922-928.
26. Roberts CGP, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults-a meta analysis. Journal Gerontol. 2007, 62A(8):879-887.
27. Tang M, Chen Y, Krewski D. Gender-related differences in the association between socioeconomic status and self-reported diabetes. Inter J Epidemiol. 2003, 32:381-385.
28. van der Meer JBW, Mackenbach JP. The care and course of diabetes: differences according to level of education. Health Policy. 1999, 46:127-141.
29. Wijk JPH, de Koning EJP, Martens EP. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003, 23:1744-1749.
30. Irons BK, Greene RS, Mazzolini TA. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy. 2006, 26(2):168-181.
31. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004, 164:2097-2104.
32. Baessler A, Fischer M, Huf V. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. Int J Cardiol. 2005, 101(2):293-298.